NCT06530290: Mirtazapine for Anxiety in Parkinson's Disease
Overview
Mermaid diagram (expand to render)
This Phase 2 clinical trial (NCT06530290) evaluates mirtazapine, a noradrenergic and specific serotonergic antidepressant, for the treatment of anxiety in Parkinson's disease (PD)[@nct06530290]. Anxiety is one of the most common non-motor symptoms in PD, affecting up to 40% of patients, yet treatment options remain limited due to the sensitivity of PD patients to traditional anxiolytic medications.
Mirtazapine represents a promising therapeutic approach because it modulates both noradrenergic and serotonergic systems—pathways known to be affected in PD—and has a favorable side effect profile compared to traditional SSRIs and benzodiazepines.
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT ID | NCT06530290 |
| Phase | Phase 2 |
| Status | Recruiting |
| Intervention | Mirtazapine (15 mg once daily) |
| Condition | Parkinson's Disease, Anxiety |
| Participants | 64 (estimated) |
| Sponsor | Leila Dargahi, PharmD PhD |
| Location | Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| Start Date | June 2022 |
| Primary Completion | December 2025 |
| Completion | June 2026 |
Parkinson's Disease and Anxiety
Prevalence and Impact
Anxiety disorders in Parkinson's disease represent a significant non-motor complication:
- Prevalence: 25-40% of PD patients meet criteria for anxiety disorders
- Types: Generalized anxiety disorder (GAD), panic disorder, social anxiety
- Underdiagnosis: Often unrecognized due to overlap with motor symptoms[@bruneau2011]
Anxiety in PD differs from primary anxiety disorders in several ways:
Disease-related etiology: Linked to neurochemical changes (dopamine, norepinephrine, serotonin)
Motor fluctuation association: Often worsens during "off" periods
Psychological reaction: Response to disability and functional impairment
Treatment-induced: Some PD medications can trigger anxiety[@pontone2009]Neurobiological Basis
The neurobiological basis of anxiety in PD involves multiple neurotransmitter systems:
Dopaminergic dysfunction:
- Loss of dopaminergic neurons in the substantia nigra affects mesocortical pathways
- Reduced dopamine in prefrontal cortex contributes to anxiety symptoms
- Correlation between striatal dopamine deficiency and anxiety severity
Noradrenergic dysfunction:
- Locus coeruleus degeneration is an early feature of PD
- Norepinephrine modulation of anxiety circuits is impaired
- The noradrenergic system regulates stress response and arousal[@ressler2004]
Serotonergic dysfunction:
- Raphe nuclei are affected in PD
- Serotonin regulates mood and anxiety
- SSRIs show modest efficacy in PD anxiety[@menza2010]
Current Treatment Challenges
Current treatment options for anxiety in PD have significant limitations:
| Treatment | Limitations |
|-----------|-------------|
| SSRIs/SNRIs | Limited efficacy, potential worsen motor symptoms |
| Benzodiazepines | Risk of falls, sedation, cognitive impairment |
| Buspirone | Modest efficacy |
| CBT | Access barriers, variable response |
This highlights the need for novel therapeutic approaches like mirtazapine that can target multiple neurotransmitter systems simultaneously.
Mirtazapine: Pharmacology
Mechanism of Action
Mirtazapine is a tetracyclic antidepressant with a unique pharmacological profile:
Primary mechanisms:
- Alpha-2 adrenergic autoreceptor antagonism: Increases norepinephrine release
- 5-HT2 receptor antagonism: Enhances serotonergic transmission
- 5-HT3 receptor antagonism: Reduces side effects (nausea, insomnia)
Receptor binding profile:| Receptor | Affinity | Effect |
|----------|----------|--------|
| α2-adrenergic | High antagonist | ↑ Norepinephrine |
| 5-HT2A | High antagonist | ↑ Serotonergic |
| 5-HT2C | High antagonist | Anxiolytic, anorectic |
| 5-HT3 | Moderate antagonist | Reduces nausea |
| H1 | High antagonist | Sedation |
Advantages for PD
Mirtazapine has several properties that make it attractive for PD anxiety:
Noradrenergic enhancement: Directly targets the impaired noradrenergic system in PD
Sleep improvement: H1 antagonism can improve sleep continuity
Weight stabilization: May help with PD-related weight loss
Minimal drug interactions: Favorable for PD patients on multiple medications
Lower seizure risk: Compared to older antidepressants[@fritea2023]Clinical Experience in PD
Prior studies have evaluated mirtazapine in Parkinson's disease:
Depression in PD:
- Mirtazapine has shown efficacy for PD depression
- Improved mood without worsening motor symptoms
- Good tolerability in PD populations[@chen2017]
Sleep in PD:
- Sedating properties can improve sleep fragmentation
- May reduce nighttime disability
- Does not worsen periodic limb movements
Trial Design
Study Population
Inclusion criteria:
- Men and women over 17 years old
- Parkinson's disease diagnosis (UKPDSBB criteria)
- Mild/moderate PD (Hoehn and Yahr score 1-3)
- Self-report or clinical diagnosis of anxiety
- Signed informed consent
Exclusion criteria:
- Pregnant or lactating women
- Disease onset less than 1 year
- Unstable PD medication (last 2 weeks)
- Deep brain stimulation (DBS)
- Other neurodegenerative diseases (MSA, Huntington's)
- Major depressive disorder
- SSRIs, SNRIs, benzodiazepines, β-blockers (last 4 weeks)
- MAO inhibitors
- Alcohol/substance abuse
- Acute stress (last 3 months)
- Suicide history
- Cardiovascular disease
- Liver/kidney disorders
Treatment Arms
The trial uses a randomized, double-blind, placebo-controlled design:
| Arm | Intervention | Dose | Duration |
|-----|--------------|------|----------|
| Treatment | Mirtazapine | 15 mg daily | 12 weeks |
| Control | Placebo | N/A daily | 12 weeks |
Primary Endpoints
Anxiety assessment:
- Hamilton Anxiety Rating Scale (HAM-A) at baseline, week 4, and week 12
- Parkinson Anxiety Scale (PAS) at baseline, week 4, and week 12
HAM-A is the gold standard for anxiety measurement:
- 14 items, scored 0-4 each
- Total score range: 0-56
- Mild anxiety: 14-17
- Moderate anxiety: 18-24
- Severe anxiety: ≥25
Secondary Endpoints
| Outcome | Instrument | Timepoints |
|---------|------------|------------|
| Depression | Hamilton Depression Rating Scale (HAM-D) | Baseline, week 4, week 12 |
| Fatigue | Parkinson's Disease Fatigue Scale (PDFS) | Baseline, week 4, week 12 |
| Sleep | Parkinson's Disease Sleep Scale (PDSS) | Baseline, week 4, week 12 |
| Quality of Life | PDQL Questionnaire | Baseline, week 4, week 12 |
Scientific Rationale
Targeting Noradrenergic Dysfunction
The rationale for mirtazapine in PD anxiety centers on its noradrenergic effects:
α2-adrenoceptor antagonism:
- Increases norepinephrine release in the prefrontal cortex
- Enhances anxiety regulation in limbic circuits
- May compensate for locus coeruleus degeneration
Mechanistic advantages:
- Direct pharmacological targeting of the impaired system
- Unlike SSRIs, which primarily affect serotonin
- Potential for greater efficacy in PD-specific anxiety[@nutt2008]
Serotonergic Modulation
The serotonergic effects of mirtazapine provide additional benefits:
- 5-HT2A antagonism: May reduce anxiety and improve mood
- 5-HT2C antagonism: Anxiolytic effects
- 5-HT3 antagonism: Reduces nausea and other GI side effects
- Enhanced serotonergic transmission without serotonin release
Sleep Benefits
PD patients frequently experience sleep fragmentation:
- Mirtazapine's H1 antagonism promotes sleep
- May improve overnight motor symptoms
- Could enhance daytime function
- Does not disrupt sleep architecture
Non-Motor Symptoms in Parkinson's Disease
Comprehensive Burden
Parkinson's disease involves numerous non-motor symptoms that impact quality of life:
| Category | Symptoms |
|----------|----------|
| Neuropsychiatric | Depression, anxiety, apathy, psychosis |
| Sleep | Insomnia, RBD, restless legs, daytime sleepiness |
| Autonomic | Orthostatic hypotension, constipation, urinary dysfunction |
| Sensory | Hyposmia, pain, visual disturbances |
| Cognitive | Executive dysfunction, memory impairment, dementia[@kalia2015] |
Anxiety as a Therapeutic Target
Treating anxiety in PD provides multiple benefits:
Quality of life: Anxiety significantly impairs daily function
Motor symptoms: Anxiety can worsen motor fluctuations
Caregiver burden: Anxiety increases caregiver stress
Disease progression: May influence neurodegenerative processes
Treatment adherence: Anxiety affects medication compliance[@barone2009]Safety Considerations
Mirtazapine Safety Profile
Mirtazapine's established safety profile supports its evaluation in PD:
Common adverse effects:
- Somnolence (due to H1 antagonism)
- Weight gain
- Dry mouth
- Constipation
- Dizziness
Less common but important:
- Orthostatic hypotension (α2 blockade)
- Rare neutropenia (requires monitoring)
- Suicidal ideation (monitor in vulnerable patients)
PD-Specific Considerations
Special considerations for the PD population:
Motor effects:
- Monitor for worsening of motor symptoms
- May interact with dopaminergic medications
- Generally considered motor-safe
Cognitive effects:
- Consider impact on cognition
- Monitor for sedation
- May affect driving safety
Cardiovascular:
- Monitor blood pressure
- Assess orthostatic symptoms
- Review cardiac history
Drug Interactions
Key interactions to monitor in PD patients:
- May enhance sedative effects of dopaminergic medications
- Potential interaction with MAO-B inhibitors
- Caution with other serotonergic agents
- Monitor with drugs affecting QT interval
Future Directions
Implications for PD Treatment
If successful, this trial could establish mirtazapine as a first-line treatment for PD anxiety:
Clinical practice impact:
- Provides evidence-based option for anxiety
- Addresses an unmet need in PD care
- May improve overall treatment outcomes
Research directions:
- Combination with dopaminergic therapy
- Comparison with SSRIs/SNRIs
- Long-term efficacy and safety
- Effects on disease progression
Biomarker Development
Future studies may incorporate:
- Neuroimaging markers of anxiety circuits
- CSF neurotransmitter levels
- Genetic predictors of response
- Autonomic function measures
Conclusion
The NCT06530290 trial represents an important step in addressing anxiety in Parkinson's disease, one of the most common and debilitating non-motor symptoms. By evaluating mirtazapine—a noradrenergic and serotonergic modulator—this trial tests a mechanistically targeted approach that addresses the neurobiological basis of PD anxiety.
The scientific rationale is compelling: mirtazapine directly enhances noradrenergic neurotransmission, which is impaired due to locus coeruleus degeneration in PD, while also providing serotonergic modulation and sleep benefits. The established safety profile of mirtazapine in general populations supports its evaluation in the often-medically complex PD patient population.
Given the high prevalence of anxiety in PD and the limitations of current treatment options, successful results from this trial could significantly improve the standard of care for Parkinson's disease patients suffering from anxiety.
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Anxiety Disorders in Neurodegeneration](/mechanisms/anxiety-neurodegeneration)
- [Noradrenergic System](/mechanisms/noradrenergic-system)
- [Serotonin and Parkinson's Disease](/mechanisms/serotonin-parkinsons)
- [Clinical Trials Dashboard](/clinical-trials/dashboard)
- [Non-Motor Symptoms in PD](/mechanisms/non-motor-symptoms-pd)
- [Mirtazapine](/therapeutics/mirtazapine)
External Links
- [ClinicalTrials.gov - NCT06530290](https://clinicaltrials.gov/study/NCT06530290)
- [Shahid Beheshti University of Medical Sciences](https://www.sbmu.ac.ir/)
References
[Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients - ClinicalTrials.gov (2024)](https://clinicaltrials.gov/study/NCT06530290)
[Stutz PF, et al. Mirtazapine for the treatment of anxiety disorders. Journal of Clinical Psychiatry (2007)]
[Bruneau MA, et al. Anxiety and depression in Parkinson's disease. Journal of Neurology (2011)]
[Pontone GM, et al. Anxiety in Parkinson's disease. Movement Disorders (2009)]
[Menza M, et al. Depression and anxiety in Parkinson disease. Journal of Neuropsychiatry (2010)]
[Chen Y, et al. Mirtazapine for the treatment of Parkinson's disease depression. Parkinsonism and Related Disorders (2017)]
[Fritea L, et al. Mirtazapine in neurological disorders. Brain Sciences (2023)]
[Nutt DJ, et al. The neurobiology of anxiety disorders. Current Topics in Behavioral Neurosciences (2008)]
[Ressler KJ, et al. Norepinephrine and anxiety. CNS Drugs (2004)]
[Barone P, et al. Parkinson's disease complications and non-motor symptoms. Lancet Neurology (2009)]
[Kalia LV, Lang AE. Parkinson's disease. Lancet (2015)]
[Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease. Lancet Neurology (2007)]